Manufacturer

• Produced by: Industria Farmaceutica Galenica Senese (IFGS).
• Country of Origin: Italy
• Distributed by: Authorized distributors worldwide, depending on the region.

Composition

• Each 4 ml vial contains:
  • Active ingredient: Glutathione (reduced form) – 600 mg
  • Other ingredients: Sodium hydroxide (for pH adjustment) and water for injection

Indications

TAD-600 (Glutathione) is a powerful antioxidant used in various clinical applications to protect cells from oxidative stress and support detoxification processes. Indications include:

• Management of liver diseases, including alcoholic liver disease, fatty liver, and hepatitis
• Detoxification support for patients exposed to toxins, heavy metals, or chemotherapy
• Adjunct therapy in neurodegenerative diseases, such as Parkinson’s disease
• Skin brightening (off-label use in some regions)
• Supportive therapy in chronic fatigue syndrome and oxidative stress-related conditions

Dosage and Administration

• Administration route: Intravenous (IV) or intramuscular (IM)
• Dosage:
  • For liver support: 600 mg IV/IM daily or as prescribed
  • For detoxification: 600–1200 mg IV, 2–3 times per week
  • For skin brightening (off-label): 600–1200 mg IV once or twice weekly, often combined with Vitamin C
• Preparation: Reconstitute the powder with 4 ml of sterile diluent. Use immediately after preparation
• Duration of therapy: Varies by condition (weeks to several months)

Contraindications

• Known hypersensitivity to glutathione or any formulation component
• Use in pregnancy or breastfeeding without medical supervision
• History of severe allergic reactions to similar substances

Precautions and Warnings

• Caution in renal impairment due to risk of accumulation
• Monitor liver function tests regularly
• Do not use as monotherapy in severe disease states
• Asthmatic patients may be at risk of bronchospasm
• Off-label use (e.g., skin whitening) requires medical oversight

Adverse Effects

• Local reactions: Pain, swelling, redness at injection site
• Allergic reactions: Rash, itching, rarely anaphylaxis
• Respiratory: Mild bronchospasm (rare)
• Neurological: Headache or dizziness (rare)

Drug Interactions

• May potentiate effects of certain chemotherapeutic agents – consult oncology specialist
• No significant interactions known, but always disclose all medications to the healthcare provider

Pregnancy and Lactation

Use only under medical advice if pregnant or breastfeeding. Safety profile not well-established in these populations.

Overdose

Symptoms such as nausea, vomiting, or dizziness may occur. Typically self-limiting. Provide supportive care if needed.

Storage

• Store at 15–25°C (59–77°F)
• Protect from moisture and light
• Do not freeze
• Use reconstituted solution immediately

Scientific References

• Glutathione and liver disease – clinical significance
• Antioxidant properties of glutathione and its clinical applications

The post TAD-600 mg/4ml (Glutathione) – 10 vials appeared first on MeDank Online Shop.

Composition

Each ampoule of Tationil contains 600 mg of reduced Glutathione in 4 ml of sterile solution. The package includes 10 ampoules and 10 corresponding vials of diluent for reconstitution. Other excipients include sodium hydroxide for pH adjustment and water for injections.

Description

Tationil is a pharmaceutical-grade Glutathione product used for antioxidant support, detoxification, and skin health. Glutathione is a naturally occurring tripeptide composed of glutamine, cysteine, and glycine. It plays a vital role in cellular defense, free radical neutralization, and metabolic regulation.

Indications

• Supportive treatment for liver detoxification
• Adjunct therapy in chemotherapy-induced toxicity
• Immune system support in chronic illness
• Adjunct in treatment of chronic fatigue syndrome and neurodegenerative diseases
• Skin brightening (off-label use under medical supervision)

Pharmacological Action

Glutathione acts as a potent antioxidant by reducing reactive oxygen species (ROS), maintaining redox balance, and detoxifying xenobiotics through conjugation. It is involved in DNA synthesis, protein repair, and immune regulation.

Dosage and Administration

• Route: Intravenous (IV) or intramuscular (IM) injection only
• Typical Dosage: 600 mg to 1200 mg 1–3 times per week, depending on indication and physician’s guidance
• Preparation: Reconstitute lyophilized powder with provided diluent before administration

Contraindications

• Known hypersensitivity to Glutathione or excipients
• Asthma (due to rare reports of bronchospasm)
• Severe renal or hepatic impairment unless prescribed under strict medical supervision

Warnings and Precautions

• Use caution in patients with renal insufficiency
• Monitor liver enzymes and renal function in long-term use
• IV use should only be done in a clinical setting by trained professionals

Adverse Reactions

• Common: Headache, dizziness, mild gastrointestinal discomfort
• Local: Injection site pain or irritation
• Rare but serious: Allergic reactions, bronchospasm, rash, or anaphylaxis

Drug Interactions

• May interact with chemotherapy agents; consult an oncologist before use
• May reduce oxidative stress markers, which could alter the efficacy of certain pro-oxidant therapies

Pregnancy and Lactation

There is insufficient data on the safety of Glutathione during pregnancy and breastfeeding. Use only if clearly necessary and under medical supervision.

Overdose

Symptoms may include gastrointestinal upset, headache, dizziness, or hypotension. Supportive care is recommended. Seek immediate medical attention in case of overdose.

Storage Conditions

• Store at 15°C to 25°C (59°F to 77°F)
• Protect from direct light and moisture
• Do not freeze
• Use immediately after reconstitution; discard any unused solution

Scientific References

• Therapeutic applications of Glutathione – PubMed
• Glutathione: Overview of its clinical applications – NCBI

The post Tationil (Glutathione) 600mg/4ml 10 ampoules + 10 flasks appeared first on MeDank Online Shop.

Esafosfina is a high-dose injectable form of fosfomycin sodium, a broad-spectrum bactericidal antibiotic used in the treatment of severe bacterial infections, particularly when resistance to standard therapies is suspected or confirmed.

Composition

• Active ingredient: Fosfomycin sodium – 10 g per vial
• Excipients: Sodium hydroxide or hydrochloric acid (for pH adjustment), water for injection (for reconstitution)

Pharmaceutical Form

Powder for solution for intravenous injection or infusion. Upon reconstitution, forms a clear to pale yellow sterile solution.

Therapeutic Indications

• Complicated urinary tract infections (e.g. pyelonephritis, recurrent cystitis)
• Lower respiratory tract infections (e.g. pneumonia)
• Intra-abdominal infections (as part of combination therapy)
• Skin and soft tissue infections (e.g. diabetic foot infections)
• Bone and joint infections (off-label, in multidrug-resistant organisms)
• Prophylaxis in major surgery with high infection risk

Mechanism of Action

Fosfomycin inhibits bacterial cell wall synthesis by irreversibly blocking the enzyme UDP-N-acetylglucosamine enolpyruvyl transferase (MurA). This results in rapid bacterial lysis. It is bactericidal against Gram-negative and Gram-positive pathogens, including ESBL-producing Enterobacteriaceae and MDR Pseudomonas aeruginosa.

Pharmacokinetics

• Distribution: Wide distribution including lungs, kidneys, liver, bone, and CSF
• Half-life: ~2–3 hours (prolonged in renal impairment)
• Elimination: Renal (unchanged in urine); dose adjustment required in renal insufficiency

Contraindications

• Hypersensitivity to fosfomycin or any component of the formulation
• Severe renal insufficiency (CrCl < 20 mL/min), unless benefits outweigh risks
• Dialysis patients without close monitoring

Warnings and Precautions

• Risk of hypokalemia with prolonged or high-dose therapy — monitor electrolytes
• Potential for neurotoxicity (confusion, seizures) at high concentrations, especially in renal impairment
• Use caution in pregnancy and lactation; safety data is limited but no evidence of teratogenicity in animal studies
• Monitor liver enzymes and renal function during prolonged treatment

Drug Interactions

• Metoclopramide may reduce absorption of oral fosfomycin (not relevant for IV form)
• Risk of additive nephrotoxicity with other renally excreted antibiotics (e.g., aminoglycosides)
• Can increase exposure to certain antivirals (tenofovir, adefovir) — monitor renal function

Adverse Effects

• Common: Diarrhea, nausea, rash, headache, injection site inflammation
• Less common: Confusion, dizziness, elevated liver enzymes, hypokalemia
• Rare but serious: Seizures, anaphylaxis, C. difficile-associated diarrhea

Pregnancy and Lactation

Fosfomycin crosses the placenta. Animal studies have not shown teratogenic effects, but data in pregnant women is limited. Use only if clearly needed. Caution is also advised during lactation as excretion into breast milk is unknown.

Dosage and Administration

• Standard adult dose: 4–8 g IV every 8–12 hours (depending on infection type and severity)
• Severe infections: Up to 12–16 g/day in divided doses (under strict supervision)
• Infusion time: Over 30–60 minutes; reconstitute in 100–250 ml of suitable diluent
• Renal impairment: Dose adjustment required per creatinine clearance

Instructions for Use

• Dissolve the powder in sterile water for injection or 0.9% NaCl solution
• Shake gently until fully dissolved
• Use the reconstituted solution immediately; discard any unused portion

Storage

• Store unopened vials below 25°C (77°F), protected from light and moisture
• Do not freeze
• Keep out of reach of children

Scientific References

• Efficacy of Fosfomycin in Severe Multidrug-Resistant Infections – NCBI
• Intravenous Fosfomycin: Clinical Use and Pharmacokinetics – PubMed

Disclaimer

This information is intended for educational purposes only and does not replace professional medical advice. Always consult a licensed healthcare provider before starting any new treatment.

The post Esafosfina 10 gr. vial appeared first on MeDank Online Shop.